



Attorney Docket No.: 27253U

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Art Unit: 1625

ULRICH

Examiner: RAHMANI, N.

Appl. No.: 10/573,202

Filed: March 24, 2006

For: **IMIDAZOPYRIDINE-DERIVATIVES AS INDUCIBLE NO-SYNTASE
INHIBITORS**

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

An Information Disclosure Statement is submitted herewith pursuant to 37 C.F.R. 1.97-1.98. Please note the following particulars: [NOTE: One only of items a, b, c, and d must be checked.]

☐ a. The enclosed statement is being filed within three months of the filing date of a national application, or within three months of the date of entry into the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing date of a first Office Action on the merits, whichever event occurs last.

☒ b. The enclosed statement is being filed after a first action on the merits but before the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311.

The enclosed statement is accompanied by [check one]:

☐ i. a certification in part (e) below as specified in 37 C.F.R. 1.97(e), or

☒ ii. a check in the amount required by 37 C.F.R. 1.17(p).

☐ c. The enclosed statement is being filed after the mailing date of a final action under 37 C.F.R. 1.113, or a notice of allowance under 37 C.F.R. 1.311, but before payment of the issue fee.

04/23/2007 SZEWDIE1 00000071 10573202

01 FC:1806

180.00 0P

☐ Certification report(e) below; and
☐ a check in the amount as required by 1.17(p).

☐ d. The enclosed statement is being filed pursuant to 37 C.F.R. 1.97(i), for placement in the file.

☐ e. Certification [Check one] [Certification is required only if box (b)(i) or box (c) is checked.]

☐ I hereby certify that each item of information contained in the enclosed Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement,

or

☐ I hereby certify that no item of information in the enclosed Information Disclosure Statement herewith was cited in a communication from a foreign patent office in a counterpart foreign application, or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 C.F.R. 1.56(c) more than three months prior to the filing of this Information Disclosure Statement.

or

☐ Appropriate certification is attached.

[~~XXX~~] f. If no check is enclosed and a fee is due in connection with this communication or if the check enclosed is insufficient, the Commissioner is authorized to charge any fee or additional fee due in connection with this communication to Deposit Account No. 14-0112.

[~~XXX~~] g. Copies of the documents are attached herewith with a completed Form PTO-1449.

or

[] Copies of the documents are not attached as allowed under CFR 1.98(d)(1)(2). The earlier application is identified as:

and / or


[] Copies of US Patents/Publications not attached as allowed in Official Gazette Aug. 5, 2003/ Vol. 1273, no. 1.

The Examiner is respectfully requested to cite the documents listed on the attached Form PTO-1449 in the next Office Action. In so doing, the Examiner is respectfully requested to initial in the space adjacent to the listing of each document on the Form PTO-1449, and return a copy of the initialed Form PTO-1449 with the next communication to Applicants, to confirm that these documents have been considered by the Examiner and made of record in this application.

If the Examiner has any questions or wishes to discuss this application, kindly telephone the undersigned at the below-listed number.

Respectfully submitted,

THE NATH LAW GROUP

By: 
Gary M. Nath
Registration No. 26,965
Joshua B. Goldberg
Registration No. 44,126
Sheldon M. McGee
Registration No. 50,454
Customer No. 34375

Date: April 20, 2007

THE NATH LAW GROUP

112 South West Street
Alexandria, VA 22314
(703)-548-6284

GMN/SMM\IDS2.doc



FORM PTO-1449

INFORMATION DISCLOSURE CITATIONAtty Docket
27253USerial No.
10/573,202Applicant
ULRICHFiling Date
3/24/06Group Art Unit
1625**U.S. PATENT DOCUMENTS**

Examiner Initial	Document Number	Issue Date	Name	Class	Sub-Class	Filing Date
AA						
AB						
AC						
AD						

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

AE		Cuzzocrea, et al., "Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis", <i>Eur. J. Pharm.</i> , 453 (2002), pp.119-129.
AF		Salvemini, et al., "Dual inhibition of Nitric Oxide and Prostaglandin Production Contributes to the Antiinflammatory Properties of Nitric Oxide Synthase Inhibitors", <i>J. Clin. Invest.</i> , 96 (1995), pp. 301-308.
AG		Liu, et al., "Specificity of inducible nitric-oxide synthase inhibitors: prospects for their clinical therapy", <i>Acta Pharmacol. Sin.</i> , 20 (11), 1999, pp.1052-1056.
AH		Kankuri, et al. "Suppression of Acute Experimental Colitis by a Highly Selective Inducible Nitric-Oxide Synthase Inhibitor, N-[3-(Aminomethyl)benzyl]acetamidine", <i>JPET</i> , 298 (2001), pp. 1128-1132.
AI		Tinker, et al., "1,2-dihydro-4-quinazolinamines: Potent Highly Selective Inhibitors of Inducible Nitric Oxide Synthase Which Show Antiinflammatory Activity in vivo", <i>J. Med. Chem.</i> , 46 (2003), pp. 913-916.
AJ		Ohtsuka, et al., "PPA250 {3-(2,4-difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl)Phenoxy]ethoxy}-2-phenylpyridine], a Novel Orally Effective Inhibitor of the Dimerization of Inducible Nitric-Oxide Synthase, Exhibits an Anti-Inflammatory Effect in Animal Models of Chronic Arthritis", <i>JPET</i> , 303 (2002), pp. 52-57.
AK		Hansel, et al., "A selective inhibitor of inducible nitric oxide synthase inhibits exhaled breath nitric oxide in healthy volunteers and asthmatics", <i>FASEB J</i> , 17 (2003), pp. 1298-1300.
AL		
AM		
AN		
AO		
AN		

Examiner

Date Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP ' 609.

Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to Applicant.